Abbott study links CGM use in Type 2 diabetes patients on basal insulin to 45% lower 12-month mortality risk

• Abbott flagged new real-world data linking continuous glucose monitoring use to fewer deaths in Type 2 diabetes patients on basal insulin.
• Results will be presented at EASD starting Sept. 28, 2026, supporting broader adoption of Libre in a large insulin-treated population.
• A separate observational analysis tied Libre use to fewer hospitalizations for acute diabetes events in Type 2 diabetes patients.
• Abbott also plans to present additional FreeDM2 trial analyses showing faster, sustained improvements in glucose control following Libre 3 initiation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief on September 25, 2026, and is solely responsible for the information contained therein.